0.0001USD0.00%Mkt Cap: —P/E: —2d ago
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor a…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value1.95M $
Revenue (TTM)386.00K $
Gross Profit-88.25M $
Net Income (TTM)-97.81M $
Revenue/Share0.0100 USD
Last Price0.0001 USD
Fiscal Year EndDec 2023
MR QuarterSep 2024
Employees68
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.02
EV/Revenue5.06
P/S—
P/B-0.00
EPS (TTM)-1.55
EPS (Forward)—
52W Range
—
52W High0.0001 USD
52W Low0.0001 USD
Profitability
Gross Margin0.00%
Oper. Margin-28891.71%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-776.96%
ROA-59.88%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-100.02M $
CapEx (TTM)—
FCF Margin-15011.01%
FCF Yield—
Net Debt1.95M $
Net Debt/EBITDA-0.02
Balance Sheet
Debt/Equity—
Current Ratio2.25
Quick Ratio2.05
Book Value/Sh-0.4150 USD
Cash/Share2.172 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.1:1
Split DateSep 19, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float26.83M
Insiders0.07%
Institutions9.62%
Technical
SMA 506.981 (-100.0%)
SMA 2004.845 (-100.0%)
Beta1.33
S&P 52W Chg18.16%
Avg Vol (30d)315
Avg Vol (10d)813
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—